Centre Henri Becquerel
- Address
- lock Available on a paid plan
Centre Henri Becquerel - Comprehensive Cancer Research Center
Centre Henri Becquerel is a leading comprehensive cancer center with extensive expertise in oncology and hematology research. The center conducts cutting-edge clinical trials across a broad spectrum of malignancies, with particular strength in hematologic malignancies, breast cancer, and head and neck cancers. The institution's research portfolio demonstrates a strong commitment to precision medicine approaches, including targeted therapies, immunotherapies, and novel combination strategies.
- Hematologic Malignancies: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Multiple Myeloma, and various lymphomas including Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, and Peripheral T-Cell Lymphoma
- Breast Cancer Research: HER2-positive and HER2-low metastatic breast cancer, hormone receptor-positive breast cancer, brain metastases treatment, and novel targeted therapy combinations with CDK4/6 inhibitors
- Head and Neck Squamous Cell Carcinoma: Locally advanced disease, recurrent/metastatic disease, and HPV-positive oropharyngeal cancer with immunotherapy and radiation therapy combinations
- Advanced Radiotherapy Techniques: Stereotactic radiotherapy for lung cancer, prostate cancer, and bone metastases, including combination strategies with immunotherapy and systemic agents
The center demonstrates significant expertise in translational research with a focus on molecular profiling, biomarker-driven treatment selection, and minimal residual disease (MRD) monitoring. Research initiatives include innovative approaches such as circulating tumor DNA (ctDNA) analysis, next-generation sequencing for treatment personalization, and evaluation of novel immunotherapeutic agents including bispecific antibodies and CAR T-cell therapy. The institution actively participates in international multicenter trials evaluating emerging therapies across sarcomas, neuroendocrine tumors, thyroid cancer, and various solid tumors, positioning itself at the forefront of modern cancer treatment development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 222 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 218 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Henri Becquerel
lock Showing 1 of 187 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study) | Groupe Oncologie Radiotherapie Tete Cou | Phase III | Not Recruiting | Dec 2023 | Sep 2024 |
IMP list
lock Showing 1 of 222 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 23 | Unknown | 2014-03-24 | 2025-12-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.